Subdural Hematoma Recurrence: Are You at Risk?
"A deep dive into the factors that increase the chances of repeat brain bleeds and what it means for your treatment."
Chronic subdural hematoma (CSDH), a condition where blood collects between the brain and its outer covering, is common, especially in older adults. While surgery often helps, the blood can sometimes come back, a situation known as recurrence. Knowing what makes recurrence more likely is crucial for effective treatment and peace of mind.
After surgery to remove the initial hematoma, a new membrane can form, filled with blood that enlarges the affected area, leading to the recurrence. Fortunately, initial treatments often show positive results. However, recurrence rates vary, ranging from 3% to 20%.
This article examines the latest research to identify the key factors that contribute to CSDH recurrence. By understanding these risks, patients and their families can better prepare for the road ahead and work with doctors to minimize potential complications.
Recurrence and Patient Impact
Subdural hematoma recurrence remains an important concern after treatment, particularly because it can prolong recovery and require additional medical attention. The likelihood and consequences vary with the type of hematoma, treatment approach, and individual patient factors. Patients should discuss warning signs, follow-up expectations, and personal risk factors with their clinical team.
Established Treatment Options
Burr-hole drainage with a subdural drain remains a standard treatment, although the Frontiers review reports recurrence rates approaching 10%–20%, with perioperative risks magnified in frail patients. The ARISE consensus material reports that craniotomy has been associated with the lowest recurrence but the highest morbidity and mortality, while twist-drill craniostomy has greater recurrence but lower morbidity and mortality. A 2026 consensus report reached strong agreement on surgical evacuation for hematomas with significant mass effect, conservative care for mild cases, burr-hole or twist-drill craniostomy as primary treatment, and postoperative drainage after evacuation.
A Long History of Discovery
The history of chronic subdural hematoma extends nearly 350 years from Johann Jakob Wepfer's first description. Historical accounts show that explanations of its origin changed over time, including Virchow's description and later recognition that chronic subdural hematoma may be traumatic but is often associated with severe brain degeneration. Experimental work described a spontaneous, expanding subdural hematoma enclosed by internal and external neomembranes, appearing by Day 3, peaking at Day 7, and lasting beyond Day 14.
What Factors Increase the Risk of CSDH Recurrence?
A recent study analyzed data from 136 patients who underwent surgery for CSDH. The goal was to pinpoint specific characteristics that made recurrence more likely. The study considered various factors, including patient demographics, medical history, and detailed analysis of brain scans.
- Hematoma Size: Larger hematomas, specifically those with a maximum thickness exceeding 20mm, were significantly associated with higher recurrence rates. Think of it like this: a larger initial bleed may indicate a more aggressive underlying condition or a greater disruption of blood vessels, making re-bleeding more likely.
- Hematoma Density: The density of the hematoma, as seen on brain CT scans, also played a role. High-density or mixed-density hematomas (meaning they contained a mix of fresh and older blood) were linked to a higher chance of recurrence. This suggests that active bleeding or repeated small bleeds within the hematoma increase the risk of it coming back.
- Surgical Technique: Interestingly, the study hinted that surgeries using two burr holes (small holes drilled in the skull to drain the hematoma) might have a slightly higher recurrence rate than those using a single hole, although this wasn't statistically significant. One possible explanation is that two holes could, in some cases, lead to a larger accumulation of air after surgery, potentially contributing to recurrence.
An Evolving Evidence Base
Recent research continues to examine why chronic subdural hematomas recur and how treatment outcomes can be improved. Reviews and clinical studies suggest that recurrence is a meaningful outcome rather than a minor postoperative inconvenience. However, findings should be interpreted in context because patient populations, treatments, outcome definitions, and follow-up periods may differ between studies.
Why Recurrence Remains Difficult
Conventional surgical evacuation can be effective, but recurrence after treatment remains common and is associated with additional morbidity and costs. Neurology Clinical Practice describes conventional management as having high rates of disease recurrence and long-term morbidity and mortality. The growing frequency of chronic subdural hematoma in high-income countries, alongside aging populations and rising antithrombotic use, adds to the challenge. Proposed risk indicators such as hematoma size and density may help frame discussions, but the available evidence does not eliminate uncertainty.
Interpreting Treatment Comparisons
Comparisons of recurrence risk are difficult because studies may evaluate different surgical techniques, patient groups, and definitions of recurrence. A treatment associated with fewer recurrences may also carry greater procedural risk, while a less invasive approach may have different trade-offs. Meaningful comparisons therefore require attention to both recurrence and broader outcomes such as morbidity, mortality, and the need for reintervention.
What Does This Mean for You?
If you or a loved one is facing surgery for a chronic subdural hematoma, understanding these risk factors can empower you to have informed conversations with your medical team. Discuss the size and density of the hematoma based on imaging results, and ask about the rationale for the chosen surgical technique.
Risk Is Multifactorial
A 2025 retrospective single-center study examined 150 consecutive patients treated surgically for chronic subdural hematoma at San Camillo Forlanini Hospital in Rome, Italy, recording clinical and radiological data and reoperation for recurrence. In contrast, a multi-institutional analysis of 1,313 surgical cases found no association between recurrence risk and age, antithrombotic medication use, or whether the hematoma was unilateral or bilateral. Another 2026 study is evaluating recurrence and reintervention after surgery alone, combined surgery and middle meningeal artery embolization, or embolization alone. Together, these reports support individualized assessment rather than assuming that one demographic or imaging feature determines recurrence.
Toward Targeted Prevention
Future prevention strategies may focus on the interaction of inflammation, coagulation dysfunction, structural brain changes, and clinical risk factors rather than on a single cause. The goal is to identify pathways that can be targeted before recurrence develops. Population-level evidence is also expanding: a 2025 study reported the first estimates of chronic subdural hematoma incidence and mortality in a large, representative U.S. population. Such data may help clarify the condition's rising public health burden and guide future research priorities.
Care Beyond the Procedure
Managing recurrence requires more than selecting an initial treatment. It also involves appropriate follow-up, recognition of changing symptoms, coordination among clinicians, and decisions that account for frailty and other health conditions. Differences in patient characteristics and treatment practices can make evidence difficult to apply uniformly. Clear communication about recurrence and when to seek urgent evaluation is therefore an important part of care.
Consequences for Patients
A report of 13 cases highlights that recurrent chronic subdural hematoma can affect patients with unilateral or bilateral disease and requires careful clinical attention. Another multicenter retrospective study examined factors associated with postoperative acute intracranial hemorrhage and chronic subdural hematoma recurrence in patients treated with burr-hole drainage, with or without irrigation. The available evidence on recurrence factors remains limited, as noted in a 2022 clinical and radiological review. These limitations make individualized follow-up especially important.
While these factors can help predict risk, they don't guarantee recurrence. Many people with large or dense hematomas have successful outcomes, and recurrence can happen even when risks seem low. Regular follow-up appointments and adherence to your doctor's recommendations are crucial for monitoring your progress and addressing any potential issues early.
This study underscores the importance of continued research into CSDH and its recurrence. By refining our understanding of the underlying mechanisms and risk factors, we can develop even more effective strategies for preventing and managing this condition, ultimately improving outcomes and quality of life for patients.